What changed this week
Patterns across the week's 81 stories; each point names the stories it rests on.
- Personalized vaccines are moving from immune responses in ovarian cancer trials toward broader testing, but remain early stage; this supports watching for licensable approaches, not near-term access.Stories 33, 43, 78
- Cell therapy work is probing stronger tumor recognition and new solid tumor targets, while safety concerns sharpen the need for careful patient selection and monitoring.Stories 9, 13, 15, 42, 46, 60, 68, 79
- Indian trial capacity is drawing new partnerships and investment, which could make overseas-developed therapies easier to test locally and bring within reach.Stories 17, 48, 55, 61
- Financial navigation results vary: one trial found no significant reduction in hardship for most patients, while another reported improved strain scores, suggesting support may need to match patients’ resources.Stories 19, 70
- More targeted treatment choices are gaining evidence or approval abroad, including biliary tract and bladder cancer options; affordability and Indian availability remain key gaps to assess.Stories 4, 31, 35, 44, 45
Clinical trials
- Retlirafusp alfa combo extended survival in advanced stomach cancerStory 5
- Shorter radiation had similar safety after breast cancer mastectomyStory 6
- Remote exercise improved quality of life for people with liver cancerStory 21
- Sitagliptin cut severe graft-versus-host disease after blood cancer transplantsStory 32
- FDA expands nogapendekin approval for bladder cancerStory 35
- Anselamimab missed its main target in amyloidosis trialStory 49
- Ponatinib and blinatumomab improved outcomes in acute lymphoblastic leukaemiaStory 51
- Radiation added no survival benefit in small cell lung cancer trialStory 52
- Navigator support raised testing among relatives at risk of hereditary cancerStory 53
- Firmonertinib showed responses in advanced non-small cell lung cancerStory 72
- Trial tested camrelizumab combination for triple-negative breast cancerStory 73
Precision oncology
- Nivolumab led to responses in advanced solid cancersStory 1
- Ovarian cancer researcher named Wistar Institute presidentStory 7
- Breast cancer metastases often gain mutations after spreadingStory 22
- Guideline recommends immunotherapy with chemotherapy for advanced biliary tract cancerStory 31
- Salvage radiation controlled recurrent prostate cancer in a phase I/II trialStory 34
- Camrelizumab lengthened time before small cell lung cancer grewStory 36
- Carboplatin improved response in some people with breast cancerStory 37
- Iberdomide triplet nearly doubles deep responses in multiple myelomaStory 50
- Serplulimab combination delayed progression in pancreatic cancerStory 67
India access
- The Survival Gap: Why India’s Breast Cancer Survival Trails the WorldStory 16
- TDB approves ₹86 crore RDI support for Peptris’ AI-driven drug developmentStory 17
- India’s biotech innovation may be hidden in its biodiversityStory 30
- NIPER Raebareli, AstraZeneca India partner to expand clinical trial sites across IndiaStory 48
- ASCO and WHO Formalize PartnershipStory 61
- Indian pharmaceutical market records 17.1% growth in September: Equirus SecuritiesStory 64
- Efficacy of Metformin With and Without Probiotics in Women With PCOSStory 65
- Zydus launches Season 3 of ‘Easiest Exam’ campaign to promote breast cancer awarenessStory 66
- Mankind Pharma to acquire 70% stake in Armed Cell Therapeutics for EUR 48 millionStory 81
Cancer-care delivery
- Blood-based model better predicted lung cancer risk in smokersStory 8
- Recent phase I trials showed longer survival for gynecologic cancer patientsStory 10
- Financial support did not ease hardship for most people with advanced cancerStory 19
- Massage and acupuncture eased pain in people with advanced cancerStory 20
- Real-world data show racial differences in cancer immunotherapy side effectsStory 54
- Cancer care partnership targets training and clinical trial accessStory 55
- Financial navigation eased money worries for people with cancerStory 70
- Childhood leukemia treatment strains families early and over timeStory 71
Cell and gene therapy
- More responsive T cells controlled melanoma tumors in miceStory 9
- Anito-cel led to responses in multiple myeloma trialStory 18
- Researchers create a mouse model of human glioblastomaStory 23
- Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed GlioblastomaStory 42
- Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell TherapyStory 59
- Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V MutationStory 60
- Autoimmune CAR T cell trials face renewed safety concernsStory 68
Solid-tumor CAR-T
- Engineered T cells shrank melanoma tumors in miceStory 15
- Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid TumorsStory 46
- Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell TherapyStory 63
- Trial pauses renew safety concerns about CAR T cells for autoimmune diseaseStory 79
- Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult ParticipantsStory 80
Cancer vaccines
- Personalized vaccines triggered immune responses in ovarian cancer trialStory 33
- Personalized vaccines triggered immune responses in ovarian cancer trialStory 43
- A Multicenter Safety and Immunogenicity Window-of-opportunity Phase 1 Interventional Trial Assessing the Combination of IDH1 Vaccine (IDH1-vac) and Vorasidenib in Adult Patients With Recurrent IDH1R132H-mutant Astrocytoma, Grade 2 - 4 (iVOCAL)Story 78
Radiopharmaceuticals
Head and neck cancer
AI and cancer
Antibody-drug conjugates
Other
- Development and validation of machine learning models for preoperative prediction of perioperative outcomes in patients with thymic epithelial tumorsStory 2
- PTK7 scaffolds DNA-PKcs to promote DNA damage response and immune evasion in triple-negative breast cancerStory 3
- FDA Approves Lirafugratinib for Previously Treated, Unresectable, Locally Advanced or Metastatic CholangiocarcinomaStory 4
- Novel Tool to Predict Primary Tumor Location in the Setting of Metastatic Cancer With Unknown PrimaryStory 11
- Predicting delirium in critically Ill patients with cancer using interpretable machine learningStory 12
- Armoring STEAP1 CAR T cells with IL-18 potentiates antitumor activity in Ewing sarcomaStory 13
- Development of a scoring system via an interpretable end-to-end neural network for prognostic stratification of patients with advanced melanomaStory 24
- Deep learning-based analysis reveals patient-level cancer therapy trajectories using single-cell PBMC chromatin imagesStory 25
- ABE-mediated dual targeting of TOX and ARHGEF1 synergistically enhances antitumor activity of tumor-infiltrating lymphocytes in PDACStory 26
- A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)Story 28
- A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)Story 29
- Divergent genomic evolution in astrocytomas and oligodendrogliomasStory 38
- Study Supports Universal Germline Genetic Testing Regardless of Age at Cancer DiagnosisStory 39
- Party With a Purpose Honors Domenick Bucci, MD, and the HEADstrong FoundationStory 40
- FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder CancerStory 44
- FDA Approves Expanded Indication for Nogapendekin Alfa Inbakicept in BCG-Unresponsive NMIBCStory 45
- A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6Story 47
- A New Way In: How Outside-the-box Science Sparked a Revolution in Targeting KRASStory 56
- Two Studies Show Breast Cancer Survival and Mortality Gaps Are Widening Between Rural and Urban AreasStory 57
- Urinary biomarkers in non-muscle invasive bladder cancer: translating multiplex and genomic liquid biopsies into clinical practiceStory 58
- Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue SarcomasStory 62
- Gastric serum biomarkers for long-term risk stratification of gastric and extra-gastric cancers: a 26-year cohort studyStory 74
- The molecular heterogeneity and clinical impact of genomic driver alterations in prostate cancerStory 75
- Machine learning uncovers previously undetectable genetic deletions in cancer panel sequencingStory 76